TherapeuticsMD, Inc. - FORM 10-Q - EX-32.2 - SECTION 906 CFO CERTIFICATION - November 16, 2009

Attached files

file filename
EX-32.1 - SECTION 906 CEO CERTIFICATION - TherapeuticsMD, Inc.dex321.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - TherapeuticsMD, Inc.dex311.htm
EX-10.8 - STANDARD SUBLEASE WITH PETERSON AND BRADFORD LLP - TherapeuticsMD, Inc.dex108.htm
EX-10.7 - PROMISSORY NOTE - TherapeuticsMD, Inc.dex107.htm
EX-10.2 - PROMISSORY NOTE - TherapeuticsMD, Inc.dex102.htm
EX-10.6 - SEATAC DIGITAL RESOURCES, INC - TherapeuticsMD, Inc.dex106.htm
EX-10.4 - AGREEMENT WITH GLOBAL ARENA CAPITAL CORP - TherapeuticsMD, Inc.dex104.htm
EX-10.3 - PROMISSORY NOTE - TherapeuticsMD, Inc.dex103.htm
EX-10.1 - PROMISSORY NOTE - TherapeuticsMD, Inc.dex101.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - TherapeuticsMD, Inc.dex312.htm
EX-10.5 - PROMISSORY NOTE - TherapeuticsMD, Inc.dex105.htm
10-Q - FORM 10-Q - TherapeuticsMD, Inc.d10q.htm
EX-3.1 - ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION - TherapeuticsMD, Inc.dex31.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of AMHN, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2009 as filed with the Securities and Exchange Commission on November 16, 2009 (the “Report”), I, Donald R. Mastropietro, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

/s/ Donald R. Mastropietro

Donald R. Mastropietro
Chief Financial Officer
November 16, 2009

A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

TherapeuticsMD, Inc. Reports